Stem Cell Transplant for Myelodysplastic Syndrome

CT
RP
Overseen ByRonald Paquette, MD
Age: Any Age
Sex: Any
Trial Phase: Phase 2
Sponsor: Ronald Paquette
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This is a single center phase II study of allogeneic stem cell transplantation in MDS who are unlikely to benefit from conventional therapy. Patients will undergo standard allogeneic stem cell transplant protocol following standard Flu/TBI 800 conditioning, PBSC transplant, and GVHD prophylaxis with PTCy and tacrolimus.

Who Is on the Research Team?

RP

Ronald Paquette, MD

Principal Investigator

Cedars-Sinai Medical Center

Are You a Good Fit for This Trial?

This trial is for people with myelodysplastic syndrome (MDS) who are not expected to benefit from standard treatments. Participants must be healthy enough for a stem cell transplant and meet other medical requirements set by the study team.

Inclusion Criteria

Patient and related donor (if applicable) must sign the Informed Consent Form; unrelated donor does not sign and this does not affect eligibility
I am eligible for a donor stem cell transplant.
I have needed more than 4 blood transfusions in the past 8 weeks.
See 4 more

Exclusion Criteria

I have previously received a hypomethylating agent as treatment.
I have had a stem cell transplant in the past.

What Are the Treatments Tested in This Trial?

Interventions

  • Allogeneic Stem Cell Transplant

Trial Overview

The study tests allogeneic stem cell transplants in MDS patients after preparing their bodies with fludarabine and total body irradiation (800 cGy). Patients receive donor cells, plus medications to prevent rejection and complications.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Single ArmExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Ronald Paquette

Lead Sponsor

Trials
2
Recruited
90+